Galera raises $30M in registered direct offering of stock and warrants

Galera Therapeutics, Inc.

Offering of 14,320,000 shares at $2.095/share plus warrants to buy 14,320,000 shares at $1.97.
Gross proceeds of $30M; net to fund avasopasem pre-commercialization, rucosopasem development, and working capital.
Closing expected February 17, 2023; 90-day lock-up for officers and directors.
Piper Sandler acted as sole placement agent; 6% placement fee on gross proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.